Letrovena (Letrozole)

Letrozole blocks the aromatase enzyme, which converts adrenal and peripheral androgens into estrogens. By inhibiting this conversion, circulating estrogen levels fall, depriving estrogen‑dependent breast cancer cells of a key growth signal and thereby slowing tumor progression.

The exact dosage of Letrovena is determined by the prescribing clinician based on the patient’s clinical status, renal and hepatic function, and treatment goals. Typical regimens involve a once‑daily oral tablet, but the prescriber sets the final dose and schedule.

Letrovena is contraindicated in pregnancy and is not recommended for breastfeeding women because it can affect estrogen levels essential for fetal development and milk production. Women of child‑bearing potential should use effective contraception during treatment.

To order Letrovena, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Letrovena (letrozole) belongs to the non‑steroidal aromatase inhibitor class, similar to anastrozole. Compared with steroidal inhibitors such as exemestane, letrozole generally offers a longer half‑life and may provide slightly higher estrogen suppression, though clinical outcomes are comparable and choice often depends on tolerability and physician preference.

Letrovena tablets should be stored at ambient temperature below 25 °C, in the original container, protected from moisture and direct light. Keep out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Letrovena is taken orally, usually once daily, with a full glass of water. It can be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels. Swallow tablets whole; do not crush or chew them.

Serious risks include bone fractures due to decreased estrogen, deep‑vein thrombosis or pulmonary embolism, severe liver injury, and rare allergic reactions such as anaphylaxis. Patients should report sudden joint pain, swelling, shortness of breath, jaundice, or rash to their healthcare provider promptly.

Letrovena should not be used in premenopausal women, individuals with known hypersensitivity to letrozole or any component of the formulation, and patients with severe hepatic impairment. Caution is also advised for those with uncontrolled cardiovascular disease or a history of thromboembolic events.